About 7% of adults in the United States are diagnosed with dry eye disease (DED). In this article, Francis Mah, MD, an ophthalmologist with Scripps Clinic in La Jolla, California, discusses the role of inflammation in DED development, shares therapeutic approaches, and explains how to tailor treatment to specific patients’ needs.
Special Collections
Clinician POV
Anti-Vascular Endothelial Growth Factor Treatment Strategies in Wet Age-Related Macular Degeneration
Ehsan Rahimy, MD, from Stanford University, California, discusses approved and pipeline vascular endothelial growth factor (VEGF) inhibitor treatments for the management of wet age-related macular degeneration (AMD).
Nonproliferative diabetic retinopathy (NPDR) may lead to complete loss of vision. However, diagnostic accuracy and newer treatment strategies may help prevent this and other vision-threatening events. In this article, Rishi P. Singh, MD, president of Cleveland Clinic Martin North Hospital in Stuart and Cleveland Clinic Martin South Hospital in Martin County, Florida, shares his views on the recent advances and challenges in the treatment of NPDR with anti-vascular endothelial growth factor injections.
Charles C. Wykoff, MD, PhD, a board-certified Medical and Surgical Retina Specialist and ophthalmologist with Retina Consultants of Texas, discusses the benefits of the additive effect seen in dual Ang-2/VEGF-A inhibition for the treatment of exudative retinal diseases.
Michael A. Singer, MD, of the University of Texas Health Science Center at San Antonio, discusses current vascular endothelial growth factor (VEGF) inhibitor treatments, as well as those in development, for the management of wet age-related macular degeneration (AMD).
